eClinix

Healthcare organisations fail to optimise patient referrals which wastes resources, in some cases up to 40% of first hospital eye appointments are deemed by clinicians as unnecessary, resulting in significant costs and drain on specialist clinical resources. eClinix is a niche decision support application that facilitates vetting of Ophthalmology referrals at the point of entry into a hospital. The system enhances a clinical user’s capability and capacity to efficiently process each referral into the next stages of the patient pathway, freeing up specialist Ophthalmology resource and improving on vetting decision consistency, speed and quality to save operating costs. It comprises an application that can be accessed from a within a hospital based electronic health record or alternative system that is used to vet and process referrals into appropriate hospital clinics. At the core of the product are regulated AI algorithms that that are trained on processing narrative driven referral information against past clinical outcomes to ensure adherence to gold standards and local clinical decision-making protocols. eClinix support Ophthalmologists to vet referrals and ultimately automates processing of incoming referrals with integration of downstream primary care referral enhancing decision support, relieving workforce pressure while improving efficiency through load balancing of clinic capacity. eClinix reduces waiting times - patients will go automatically to an appropriate expert in an appropriate setting in a consistent, timely manner thus increase accuracy of likely diagnosis and fast tracking of urgent referrals. The result is reduction in morbidity, reducing unwarranted variation and improvement in patient experience. In time this leads to trust and confidence and therefore better patient adherence and compliance. Patients will experience better clinical outcomes reduced, morbidity and mortality as a result. eClinix is undergoing certification against regulatory bodies in the US and Europe with an anticipated production release in 2021.